[{"orgOrder":0,"company":"VisiRose","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VisiRose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VisiRose \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VisiRose \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Rose Bengal Disodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing is intended to support the clinical development of VisiRose’s formulated Rose Bengal Disodium for the treatment of infectious keratitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 14, 2025

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $3.0 million

                          Deal Type : Financing

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 26, 2016

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 23, 2015

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 22, 2014

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 04, 2013

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Provectus Biopharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank